Abstract

A COMPARATIVE STUDY ON EFFICACY AND SAFETY OF TENELIGLIPTIN AND CANAGLIFLOZIN IN TYPE 2 DIABETES PATIENTS

Dr. B. Hemalatha*, Shailesh Harishchandra Kendre, Manish Dhakar, Mahesh Gomasa, Meda Yashaswini Sowmya, Vadde Sahithi, Habeeb Rahman Khan, Shaikh Mohammed Taher, Mohammed Abdul Qader and Hanan Baig

Abstract

Background: Type 2 Diabetes Mellitus is a very common chronic condition that needs good glycemic management to avoid complications. This study compared the efficacy and safety of two commonly prescribed medications in the management of T2DM: Teneligliptin and Canagliflozin. Methods: This was a prospective, comparative, observational study conducted for six months in 140 T2DM patients attending the outpatient department. The patients were classified into two groups of 70 each: the first group received Teneligliptin, and the second received Canagliflozin. HbA1c and fasting blood sugar were recorded at baseline and after three months of treatment. The adverse events monitored during this study included hypoglycaemia, urinary tract infections, dehydration, and gastrointestinal problems. Results: Both Teneligliptin and Canagliflozin reduced HbA1c by 1.5% and fasting blood glucose by 25 mg/dL. A slight advantage of Canagliflozin over Teneligliptin was observed with regard to achieving the target HbA1c (

Keywords: Teneligliptin, Canagliflozin, Type 2 Diabetes Mellitus, glycemic control, HbA1c, fasting blood glucose, efficacy, safety.